Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414832 | 0.87 | SIRT2 (0.37) | SIRT2ALOX5APLCKNPC1RAB9A | |
| SCHEMBL4024355 | 0.83 | SIRT2 (0.41) | SIRT2ACSS2NPC1RAB9A | |
| SCHEMBL5678341 | 0.77 | KDM4E (0.46) | SIRT2KMT2A | |
| SCHEMBL1414929 | 0.77 | SIRT2 (0.36) | SIRT2LCKNPC1RAB9AKMT2A | |
| SCHEMBL5682251 | 0.75 | LMNA (0.42) | SIRT2ACSS2RAB9AKMT2A | |
| SCHEMBL313125 | 0.75 | ACSS2 (0.43) | SIRT2ACSS2 | |
| SCHEMBL1414925 | 0.74 | SIRT2 (0.34) | SIRT2 | |
| SCHEMBL4030987 | 0.74 | MEN1 (0.51) | SIRT2NPC1RAB9AKMT2A | |
| SCHEMBL4024513 | 0.73 | CA12 (0.38) | SIRT2 | |
| SCHEMBL1829222 | 0.73 | SIRT2 (0.47) | SIRT2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1344777-B1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-6960586-B2 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1344777-A1 | IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Takeda Chemical Industries, Ltd. (JP) | 2003-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024039-A1 | Imidazole derivatives, process for their preparation and their use | CYP17A1, HSD17B7, CYP51A1 | SIRT2 2362/4885ALOX5AP 1498/4885ACSS2 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.